KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares OutstandingShares Repurchased
Ratios

Royalty Pharma (RPRX) Non-Current Receivables: 2019-2025

Historic Non-Current Receivables for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $15.8 billion.

  • Royalty Pharma's Non-Current Receivables rose 5.32% to $15.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 billion, marking a year-over-year increase of 5.32%. This contributed to the annual value of $15.1 billion for FY2024, which is 7.37% up from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Non-Current Receivables is $15.8 billion, which was up 4.16% from $15.1 billion recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Non-Current Receivables ranged from a high of $15.8 billion in Q3 2025 and a low of $12.6 billion during Q1 2021.
  • Its 3-year average for Non-Current Receivables is $14.3 billion, with a median of $14.1 billion in 2023.
  • As far as peak fluctuations go, Royalty Pharma's Non-Current Receivables increased by 17.49% in 2021, and later decreased by 7.40% in 2023.
  • Over the past 5 years, Royalty Pharma's Non-Current Receivables (Quarterly) stood at $13.7 billion in 2021, then fell by 1.64% to $13.5 billion in 2022, then increased by 4.41% to $14.1 billion in 2023, then rose by 7.37% to $15.1 billion in 2024, then grew by 5.32% to $15.8 billion in 2025.
  • Its Non-Current Receivables stands at $15.8 billion for Q3 2025, versus $15.1 billion for Q2 2025 and $15.0 billion for Q1 2025.